Breakthrough Heart Failure Treatment Developed By This Company

Tenax Therapeutics Receives FDA Clearance for TNX-103: A Significant Breakthrough in the Treatment of Pulmonary Hypertension.

The medical world is buzzing today as Tenax Therapeutics has achieved a significant milestone. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for TNX-103 (oral levosimendan), developed by Tenax. This clearance allows the initiation of Phase 3 clinical trials, providing hope for individuals sufferin…